What is the vaccine called for encephalitis tick? - briefly
«Encepur» and «FSME‑Immun» are the licensed vaccines for tick‑borne encephalitis, administered as an inactivated virus preparation in a three‑dose primary series.
What is the vaccine called for encephalitis tick? - in detail
The vaccine used to prevent tick‑borne encephalitis is marketed under the brand names Encepur and FSME‑Immun. Both formulations contain inactivated virus particles that stimulate immunity against the TBE virus.
Key characteristics:
- Active ingredients: purified, formalin‑inactivated TBE virus strains (Encepur: Neudoerfl strain; FSME‑Immun: K23 strain).
- Administration schedule: initial series of three doses; the first two doses given 1‑3 months apart, the third dose 5‑12 months after the second. Booster doses are recommended every 3–5 years, depending on age and risk exposure.
- Efficacy: clinical trials report seroconversion rates above 95 % after the primary series; long‑term protection maintained with regular boosters.
- Safety profile: most common adverse events are mild injection‑site reactions, transient headache, and low‑grade fever. Serious adverse events are rare.
- Target groups: individuals living in or traveling to endemic areas, forestry workers, hunters, hikers, and children from 1 year of age in some regions.
- Contraindications: severe allergic reaction to any vaccine component, acute febrile illness, and immunosuppression in certain cases.
Availability varies by country; Encepur is approved in Germany and several neighboring states, while FSME‑Immun is licensed in Austria, Switzerland, and other European nations. Both vaccines are administered intramuscularly, typically in the deltoid muscle. Monitoring of antibody titers can guide booster timing for high‑risk individuals.